Xiaojiao Cheng
State Key Laboratory Of Systems Medicine For Cancer
Shanghai, 200127, China
Shanghai, 200127, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
TGF-β inhibition enhances anti-tumor immunity and sensitizes PD-1 blockade therapy of bone marrow-derived myofibroblasts-induced "immunotherapy resistance" tumor model.
Journal: Cancer immunology, immunotherapy : CII
Published: February 11, 2026
TRF2 Upregulates Protein Phosphatase 2A Subunit PPP2R2C to Attenuate DNA Damage Response at Telomeres and Pericentromeres Upon Replicative Stress.
Journal: Aging and disease
Published: October 07, 2025
Significant response from fruquintinib plus anti-PD-1 immunotherapy for microsatellite stable metastatic colorectal cancer with liver and lung metastasis in the third line: case report.
Journal: Journal of gastrointestinal oncology
Published: October 20, 2023
A pancancer analysis of the clinical and genomic characteristics of multiple primary cancers.
Journal: Scientific reports
Published: June 14, 2023
The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer.
Journal: Frontiers in oncology
Published: April 20, 2022
Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors.
Journal: Journal of oncology
Published: January 22, 2022
Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer.
Journal: Frontiers in oncology
Published: December 23, 2021
Current status and future perspective of immune checkpoint inhibitors in colorectal cancer.
Journal: Cancer letters
Published: April 06, 2021
Utidelone inhibits growth of colorectal cancer cells through ROS/JNK signaling pathway.
Journal: Cell death & disease
Published: October 25, 2020
Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors.
Journal: Frontiers in immunology
Published: October 19, 2020
Last Updated: 09/26/2026